First Ebola Vaccine Approved by European Commission

THURSDAY, Nov. 14, 2019 -- The world's first Ebola vaccine has been approved by the European Commission, and it was quickly prequalified by the World Health Organization. The Ervebo vaccine is made by Merck and is being used in a " compassionate use " ...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

- A stockpile of 500,000 doses of Ebola vaccine for emergency use in outbreaks of the deadly fever is being established by the global vaccine alliance GAVI.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Vaccine alliance announces creation of Ebola vaccine stockpile of about 500,000 doses
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
[WHO] Kinshasa, 5 December 2019 - Around 2.2 million children are to be vaccinated against measles in North Kivu, the Democratic Republic of the Congo (DRC), where efforts are underway to curb the world's second-worst Ebola outbreak amid persistent insecurity.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
We report a candidate lead (compound #5: ((10R)-10-(4-hydroxyphenyl)-11,12,14,16-tetraazatetracyclo[7.7.0.02,7.011,15] hexadeca-1(16), 2(7),3,5,8,12,14-heptaen-8-ol)) with high drug-likeness score, promising lead-likeness behaviour and high median lethal dose. The candidate lead compound #5 engages in hydrogen bonding and hydrophobic interactions with VP40 active site residues. Thus, the lead compound #5 is recommended for further in vitro and in vivo validations for further consideration. PMID: 31787811 [PubMed]
Source: Bioinformation - Category: Bioinformatics Authors: Tags: Bioinformation Source Type: research
Condition:   Ebola Virus Disease Intervention:   Biological: Ad26.ZEBOV vaccine Sponsors:   Universiteit Antwerpen;   Johnson & Johnson;   Ace Africa;   Innovative Medicines Initiative;   Coalition for epidemic prepardness innovations;   University of Kinshasa Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
As the outbreak wanes, one vaccine has been approved and another has entered the next phase of testing
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
, Norheim G Abstract Today's world is characterized by increasing population density, human mobility, urbanization, and climate and ecological change. This global dynamic has various effects, including the increased appearance of emerging infectious diseases (EIDs), which pose a growing threat to global health security.Outbreaks of EIDs, like the 2013-2016 Ebola outbreak in West Africa or the current Ebola outbreak in Democratic Republic of the Congo (DRC), have not only put populations in low- and middle-income countries (LMIC) at risk in terms of morbidity and mortality, but they also have had a significant impa...
Source: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz - Category: International Medicine & Public Health Authors: Tags: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Source Type: research
The interplay between civil unrest and disease transmission is not well understood. Violence targeting healthcare workers and Ebola treatment centers in the Democratic Republic of the Congo (DRC) has been thwarting the case isolation, treatment, and vaccination efforts. The extent to which conflict impedes public health response and contributes to...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Tags: Biological Sciences Source Type: research
AbstractPurpose of ReviewAs research efforts have advanced to understand the pathophysiology of viral hemorrhagic fevers (VHF) and other epidemic viral infections and develop medical countermeasures such as vaccines, pregnant women have remained an underexamined subgroup. To better understand the implications of future outbreaks of VHF for pregnant women amidst an evolving vaccine landscape, we examine three pathogens —yellow fever, Ebola, and Lassa fever—each with different levels of evidence and understanding of disease in pregnancy and at varying stages of vaccine development.Recent FindingsThere are very li...
Source: Current Tropical Medicine Reports - Category: Tropical Medicine Source Type: research
AbstractPurpose of ReviewEbola virus infection has one of the highest overall case fatality rates of any viral disease. It has historically had an especially high case mortality rate among pregnant women and infants —greater than 90% for pregnant women in some outbreaks and close to 100 % in fetuses and newborns. The Merck recombinant vaccine against Ebola virus, termed rVSV-ZEBOV, underwent clinical trials during the 2013–2015 West Africa Ebola epidemic where it was found to be 100% efficacious. It was sub sequently used during the 2018 DRC Équateur outbreak and in the 2018 DRC Kivu Ebola which is still...
Source: Current Tropical Medicine Reports - Category: Tropical Medicine Source Type: research
More News: Ebola | Ebola Vaccine | International Medicine & Public Health | Merck | Pharmaceuticals | Vaccines | WHO